

ANTICONVULSANT STEP THERAPY

Products Affected

Step 2:

- APTIOM 200 MG TABLET
- APTIOM 400 MG TABLET
- APTIOM 600 MG TABLET
- APTIOM 800 MG TABLET
- BRIVIACT 10 MG TABLET
- BRIVIACT 10 MG/ML ORAL SOLUTION
- BRIVIACT 100 MG TABLET
- BRIVIACT 25 MG TABLET
- BRIVIACT 50 MG TABLET
- BRIVIACT 75 MG TABLET
- FYCOMPA 0.5 MG/ML ORAL SUSPENSION
- FYCOMPA 10 MG TABLET
- FYCOMPA 12 MG TABLET
- FYCOMPA 2 MG TABLET
- FYCOMPA 4 MG TABLET
- FYCOMPA 6 MG TABLET
- FYCOMPA 8 MG TABLET
- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION
- VIMPAT 10 MG/ML ORAL SOLUTION
- VIMPAT 100 MG TABLET
- VIMPAT 150 MG TABLET
- VIMPAT 200 MG TABLET
- VIMPAT 50 MG TABLET

Details

Criteria
Step 1: First line therapy should be a documented trial of two of the following formulary medications: carbamazepine, carbamazepine ER, divalproex sodium, divalproex sodium ER, gabapentin, lamotrigine, lamotrigine ER, levetiracetam, levetiracetam ER, oxcarbazepine, valproic acid, zonisamide, phenytoin, phenytoin ER, felbamate, ethosuxamide, topiramate, primidone, Dilantin, phenobarbital, Phenytek or tiagabine. Step 2: Once two of the medications listed in Step 1 have been tried, patients can receive therapy with Aptiom, Spritam, Fycompa, Briviact or Vimpat.

ANTIDEPRESSANT STEP THERAPY

Products Affected

Step 2:

- | | |
|--|---|
| <ul style="list-style-type: none"> • FETZIMA 120 MG
CAPSULE,EXTENDED RELEASE • FETZIMA 20 MG (2)-40 MG (26)
CAPSULE,EXTENDED RELEASE,24
HR,DOSE PACK • FETZIMA 20 MG
CAPSULE,EXTENDED RELEASE • FETZIMA 40 MG
CAPSULE,EXTENDED RELEASE | <ul style="list-style-type: none"> • FETZIMA 80 MG
CAPSULE,EXTENDED RELEASE • TRINTELLIX 10 MG TABLET • TRINTELLIX 20 MG TABLET • TRINTELLIX 5 MG TABLET • VIIBRYD 10 MG (7)-20 MG (23)
TABLETS IN A DOSE PACK • VIIBRYD 10 MG TABLET • VIIBRYD 20 MG TABLET • VIIBRYD 40 MG TABLET |
|--|---|

Details

Criteria	Step 1: First line therapy should be a documented trial of two of the following formulary medications: citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine, venlafaxine ER or desvenlafaxine. Step 2: Once two of the medications listed in step 1 have been tried, patient can receive therapy with Trintellix, Fetzima or Viibryd.
-----------------	--

2019 3 Tier MMP-Partners
Document: 2019 Step Therapy Criteria
Formulary ID: 19410
Last Updated: 02/2019
Effective Date: 03/01/2019

AZOPT STEP THERAPY

Products Affected

Step 2:

- AZOPT 1 % EYE
DROPS,SUSPENSION

Details

Criteria	Step 1: First line therapy should be a documented trial of formulary dorzolamide or dorzolamide/timolol. Step 2: Once dorzolamide or dorzolamide/timolol has been tried, the patient can receive therapy with Azopt.
-----------------	--

COMBIVENT STEP THERAPY

Products Affected

Step 2:

- COMBIVENT RESPIMAT 20 MCG-100 MCG/ACTUATION SOLUTION FOR INHALATION

Details

Criteria
Step 1: First line therapy should be a documented trial of formulary Anoro Ellipta. Step 2: Once Anoro Ellipta has been tried, patients can receive therapy with Combivent Respimat.

GLP-1 AGONIST STEP THERAPY

Products Affected

Step 2:

- OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR
- OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR
- TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- VICTOZA 2-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR
- VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR

Details

Criteria
Step 1: First line therapy should be a documented trial of a formulary metformin tablet or metformin ER tablet. Step 2: Once metformin tablet or metformin ER tablet has been tried, patients can receive therapy with Victoza, Trulicity, or Ozempic.

HYPOGLYCEMICS STEP THERAPY

Products Affected

Step 2:

- *acarbose 100 mg tablet*
- *acarbose 25 mg tablet*
- *acarbose 50 mg tablet*
- *alogliptin 12.5 mg tablet*
- *alogliptin 12.5 mg-metformin 1,000 mg tablet*
- *alogliptin 12.5 mg-metformin 500 mg tablet*
- *alogliptin 12.5 mg-pioglitazone 15 mg tablet*
- *alogliptin 12.5 mg-pioglitazone 30 mg tablet*
- *alogliptin 12.5 mg-pioglitazone 45 mg tablet*
- *alogliptin 25 mg tablet*
- *alogliptin 25 mg-pioglitazone 15 mg tablet*
- *alogliptin 25 mg-pioglitazone 30 mg tablet*
- *alogliptin 25 mg-pioglitazone 45 mg tablet*
- *alogliptin 6.25 mg tablet*
- AVANDIA 2 MG TABLET
- AVANDIA 4 MG TABLET
- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JANUMET 50 MG-1,000 MG TABLET
- JANUMET 50 MG-500 MG TABLET
- JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE
- JANUVIA 100 MG TABLET
- JANUVIA 25 MG TABLET
- JANUVIA 50 MG TABLET
- JENTADUETO 2.5 MG-1,000 MG TABLET
- JENTADUETO 2.5 MG-500 MG TABLET
- JENTADUETO 2.5 MG-850 MG TABLET
- JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE
- *nateglinide 120 mg tablet*
- *nateglinide 60 mg tablet*
- *pioglitazone 15 mg tablet*
- *pioglitazone 15 mg-metformin 500 mg tablet*
- *pioglitazone 15 mg-metformin 850 mg tablet*
- *pioglitazone 30 mg tablet*
- *pioglitazone 45 mg tablet*
- *repaglinide 0.5 mg tablet*
- *repaglinide 1 mg tablet*
- *repaglinide 2 mg tablet*
- SEGLUROMET 2.5 MG-1,000 MG TABLET
- SEGLUROMET 2.5 MG-500 MG TABLET

2019 3 Tier MMP-Partners
Document: 2019 Step Therapy Criteria
Formulary ID: 19410
Last Updated: 02/2019
Effective Date: 03/01/2019

- SEGLUOMET 7.5 MG-1,000 MG TABLET
- SEGLUOMET 7.5 MG-500 MG TABLET
- STEGLATRO 15 MG TABLET
- STEGLATRO 5 MG TABLET
- STEGLUJAN 15 MG-100 MG TABLET
- STEGLUJAN 5 MG-100 MG TABLET
- TRADJENTA 5 MG TABLET

Details

Criteria	Step 1: First line therapy should be a documented trial with a formulary sulfonylurea, metformin or formulary insulin (if appropriate). Step 2: Once one of these agents has been tried, patients can receive therapy with other formulary hypoglycemics such as Avandia, acarbose, Januvia, Janumet, Janumet XR, repaglinide, nateglinide, pioglitazone, pioglitazone/metformin, alogliptin, alogliptin/metformin, alogliptin/pioglitazone, Tradjenta, Jentadueto, Jentadueto XR, Invokana, Invokamet, Invokamet XR, Steglatro, Segluromet or Steglujan
-----------------	--

KRISTALOSE STEP THERAPY

Products Affected

Step 2:

- KRISTALOSE 20 GRAM ORAL PACKET
- *lactulose 10 gram oral packet*

Details

Criteria
Step 1: First line therapy should be a documented trial of formulary Constulose, lactulose, or polyethylene glycol. Step 2: Once Constulose, lactulose, or polyethylene glycol has been tried, patients can receive therapy with Kristalose packet.

2019 3 Tier MMP-Partners
Document: 2019 Step Therapy Criteria
Formulary ID: 19410
Last Updated: 02/2019
Effective Date: 03/01/2019

RANEXA STEP THERAPY

Products Affected

Step 2:

- RANEXA 1,000 MG
TABLET,EXTENDED RELEASE
- RANEXA 500 MG
TABLET,EXTENDED RELEASE

Details

Criteria
Step 1: First line therapy should be a documented trial of a formulary beta blocker or a calcium channel blocker. Step 2: Once a beta blocker or a calcium channel blocker has been tried, patients may receive therapy with Ranolazine (Ranexa).

TOPICAL IMMUNOMODULATORS STEP THERAPY

Products Affected

Step 2:

- ELIDEL 1 % TOPICAL CREAM
- *pimecrolimus 1 % topical cream*
- *tacrolimus 0.03 % topical ointment*
- *tacrolimus 0.1 % topical ointment*

Details

Criteria	Step 1: First line therapy should be a documented trial of two formulary topical corticosteroids. Step 2: Once two of these agents have been tried, patients can receive therapy with Elidel or generic topical tacrolimus.
-----------------	---

2019 3 Tier MMP-Partners
Document: 2019 Step Therapy Criteria
Formulary ID: 19410
Last Updated: 02/2019
Effective Date: 03/01/2019

TREXALL STEP THERAPY

Products Affected

Step 2:

- TREXALL 10 MG TABLET
- TREXALL 15 MG TABLET
- TREXALL 5 MG TABLET
- TREXALL 7.5 MG TABLET

Details

Criteria
Step 1: First line therapy should be a documented trial with formulary generic methotrexate. Step 2: Once generic methotrexate has been tried, patients can receive Trexall.

ULORIC STEP THERAPY

Products Affected

Step 2:

- ULORIC 40 MG TABLET
- ULORIC 80 MG TABLET

Details

Criteria
Step 1: First line therapy should be a documented trial of formulary allopurinol tablet. Step 2: Once allopurinol tablet has been tried, patients can receive therapy with Uloric.

URINARY INCONTINENCE AGENTS STEP THERAPY

Products Affected

Step 2:

- *darifenacin er 15 mg tablet,extended release 24 hr*
- *darifenacin er 7.5 mg tablet,extended release 24 hr*

Step 3:

- MYRBETRIQ 25 MG TABLET,EXTENDED RELEASE
- MYRBETRIQ 50 MG TABLET,EXTENDED RELEASE

Details

Criteria
Step 1: First line therapy should be a documented trial of formulary oxybutynin, oxybutynin ER, tolterodine or tolterodine ER. Step 2: Second line therapy should be formulary darifenacin ER. Step 3: Once oxybutynin, oxybutynin ER, tolterodine or tolterodine ER AND darifenacin ER have been tried, patients can receive therapy with Myrbetriq.

ZAFIRLUKAST STEP THERAPY

Products Affected

Step 2:

- *zafirlukast 10 mg tablet*
- *zafirlukast 20 mg tablet*

Details

Criteria	Step 1: First line therapy should be a documented trial of formulary montelukast. Step 2: Once montelukast has been tried, patients may receive therapy with zafirlukast.
-----------------	---

2019 3 Tier MMP-Partners
Document: 2019 Step Therapy Criteria
Formulary ID: 19410
Last Updated: 02/2019
Effective Date: 03/01/2019

ZIRGAN STEP THERAPY

Products Affected

Step 2:

- ZIRGAN 0.15 % EYE GEL

Details

Criteria	Step 1: First line therapy should be a documented trial of formulary generic trifluridine ophthalmic. Step 2: Once generic trifluridine ophthalmic has been tried, patients can receive therapy with Zirgan.
-----------------	--

E. Index of Covered Drugs

A

acarbose 100 mg tablet.....	6
acarbose 25 mg tablet.....	6
acarbose 50 mg tablet.....	6
alogliptin 12.5 mg tablet	6
alogliptin 12.5 mg-metformin 1,000 mg tablet.....	6
alogliptin 12.5 mg-metformin 500 mg tablet	6
alogliptin 12.5 mg-pioglitazone 15 mg tablet	6
alogliptin 12.5 mg-pioglitazone 30 mg tablet	6
alogliptin 12.5 mg-pioglitazone 45 mg tablet	6
alogliptin 25 mg tablet	6
alogliptin 25 mg-pioglitazone 15 mg tablet	6
alogliptin 25 mg-pioglitazone 30 mg tablet	6
alogliptin 25 mg-pioglitazone 45 mg tablet	6
alogliptin 6.25 mg tablet	6
APTIOM 200 MG TABLET	1
APTIOM 400 MG TABLET	1
APTIOM 600 MG TABLET	1
APTIOM 800 MG TABLET	1
AVANDIA 2 MG TABLET	6
AVANDIA 4 MG TABLET	6
AZOPT 1 % EYE DROPS,SUSPENSION	3

B

BRIVIACT 10 MG TABLET.....	1
BRIVIACT 10 MG/ML ORAL SOLUTION	1
BRIVIACT 100 MG TABLET.....	1
BRIVIACT 25 MG TABLET.....	1
BRIVIACT 50 MG TABLET.....	1
BRIVIACT 75 MG TABLET.....	1

C

COMBIVENT RESPIMAT 20 MCG-100 MCG/ACTUATION SOLUTION FOR INHALATION.....	4
--	---

D

darifenacin er 15 mg tablet,extended release 24 hr	13
darifenacin er 7.5 mg tablet,extended release 24 hr	13

E

ELIDEL 1 % TOPICAL CREAM	10
--------------------------------	----

F

FETZIMA 120 MG CAPSULE,EXTENDED RELEASE	2
FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK.....	2
FETZIMA 20 MG CAPSULE,EXTENDED RELEASE.....	2
FETZIMA 40 MG CAPSULE,EXTENDED RELEASE.....	2
FETZIMA 80 MG CAPSULE,EXTENDED RELEASE.....	2
FYCOMPA 0.5 MG/ML ORAL SUSPENSION	1
FYCOMPA 10 MG TABLET	1
FYCOMPA 12 MG TABLET	1
FYCOMPA 2 MG TABLET	1
FYCOMPA 4 MG TABLET	1
FYCOMPA 6 MG TABLET	1
FYCOMPA 8 MG TABLET	1

I

INVOKAMET 150 MG-1,000 MG TABLET	6
INVOKAMET 150 MG-500 MG TABLET	6
INVOKAMET 50 MG-1,000 MG TABLET	6
INVOKAMET 50 MG-500 MG TABLET.	6
INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE	6
INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE	6
INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE	6
INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE	6
INVOKANA 100 MG TABLET	6
INVOKANA 300 MG TABLET	6

J

JANUMET 50 MG-1,000 MG TABLET ...	6
JANUMET 50 MG-500 MG TABLET	6
JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE	6

JANUMET XR 50 MG-1,000 MG
 TABLET,EXTENDED RELEASE 6
 JANUMET XR 50 MG-500 MG
 TABLET,EXTENDED RELEASE 6
 JANUVIA 100 MG TABLET 6
 JANUVIA 25 MG TABLET 6
 JANUVIA 50 MG TABLET 6
 JENTADUETO 2.5 MG-1,000 MG
 TABLET 6
 JENTADUETO 2.5 MG-500 MG TABLET
 6
 JENTADUETO 2.5 MG-850 MG TABLET
 6
 JENTADUETO XR 2.5 MG-1,000 MG
 TABLET, EXTENDED RELEASE 6
 JENTADUETO XR 5 MG-1,000 MG
 TABLET, EXTENDED RELEASE 6
K
 KRISTALOSE 20 GRAM ORAL PACKET
 8
L
 lactulose 10 gram oral packet 8
M
 MYRBETRIQ 25 MG
 TABLET,EXTENDED RELEASE 13
 MYRBETRIQ 50 MG
 TABLET,EXTENDED RELEASE 13
N
 nateglinide 120 mg tablet..... 6
 nateglinide 60 mg tablet..... 6
O
 OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5
 ML) SUBCUTANEOUS PEN
 INJECTOR..... 5
 OZEMPIC 1 MG/DOSE (2 MG/1.5 ML)
 SUBCUTANEOUS PEN INJECTOR 5
P
 pimecrolimus 1 % topical cream..... 10
 pioglitazone 15 mg tablet..... 6
 pioglitazone 15 mg-metformin 500 mg
 tablet..... 6
 pioglitazone 15 mg-metformin 850 mg
 tablet..... 6

pioglitazone 30 mg tablet..... 6
 pioglitazone 45 mg tablet..... 6
R
 RANEXA 1,000 MG
 TABLET,EXTENDED RELEASE 9
 RANEXA 500 MG TABLET,EXTENDED
 RELEASE 9
 repaglinide 0.5 mg tablet..... 6
 repaglinide 1 mg tablet..... 6
 repaglinide 2 mg tablet..... 6
S
 SEGLUROMET 2.5 MG-1,000 MG
 TABLET 6
 SEGLUROMET 2.5 MG-500 MG TABLET
 6
 SEGLUROMET 7.5 MG-1,000 MG
 TABLET 7
 SEGLUROMET 7.5 MG-500 MG TABLET
 7
 SPRITAM 1,000 MG TABLET FOR ORAL
 SUSPENSION 1
 SPRITAM 250 MG TABLET FOR ORAL
 SUSPENSION 1
 SPRITAM 500 MG TABLET FOR ORAL
 SUSPENSION 1
 SPRITAM 750 MG TABLET FOR ORAL
 SUSPENSION 1
 STEGLATRO 15 MG TABLET 7
 STEGLATRO 5 MG TABLET 7
 STEGLUJAN 15 MG-100 MG TABLET .. 7
 STEGLUJAN 5 MG-100 MG TABLET 7
T
 tacrolimus 0.03 % topical ointment 10
 tacrolimus 0.1 % topical ointment 10
 TRADJENTA 5 MG TABLET..... 7
 TREXALL 10 MG TABLET..... 11
 TREXALL 15 MG TABLET..... 11
 TREXALL 5 MG TABLET..... 11
 TREXALL 7.5 MG TABLET..... 11
 TRINTELLIX 10 MG TABLET 2
 TRINTELLIX 20 MG TABLET 2
 TRINTELLIX 5 MG TABLET 2

TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR	5
TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR	5
U	
ULORIC 40 MG TABLET	12
ULORIC 80 MG TABLET	12
V	
VICTOZA 2-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR.....	5
VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR.....	5

VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK.....	2
VIIBRYD 10 MG TABLET	2
VIIBRYD 20 MG TABLET	2
VIIBRYD 40 MG TABLET	2
VIMPAT 10 MG/ML ORAL SOLUTION.	1
VIMPAT 100 MG TABLET	1
VIMPAT 150 MG TABLET	1
VIMPAT 200 MG TABLET	1
VIMPAT 50 MG TABLET	1
Z	
zafirlukast 10 mg tablet.....	14
zafirlukast 20 mg tablet.....	14
ZIRGAN 0.15 % EYE GEL.....	15